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Abstract The myogenic regulatory family of basic helix-loop-
helix transcription factors, including MyoD and myogenin,
functions cooperatively with the myocyte-speci¢c enhancer bind-
ing factor 2 (MEF2) family during skeletal myogenesis. Previ-
ously, using aggregated P19 cells, we have shown that myogenin
upregulates MEF2C expression while MyoD does not [Ridge-
way et al., J. Biol. Chem. 275 (2000) 41^46]. In order to iden-
tify the domain of myogenin responsible for activating MEF2C
expression, a series of chimeras of MyoD and myogenin were
generated. Only chimeras containing the C-terminal region of
myogenin were able to activate MEF2C in aggregated P19
cells, suggesting that the C-terminus of myogenin is responsible
for the regulation of speci¢c target genes. 6 2002 Federation
of European Biochemical Societies. Published by Elsevier Sci-
ence B.V. All rights reserved.
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1. Introduction
The isolation and identi¢cation of the myogenic family of
basic helix-loop-helix (bHLH) transcription factors (MRFs)
represented a major breakthrough in the ¢eld of myogenesis
[1]. The four MRFs, MyoD, myf-5, myogenin, and MRF-4,
bind E box consensus sites found in the promoters of many
muscle-speci¢c genes, and activate transcription. In addition
to E boxes, another muscle-speci¢c regulatory element, the
A+T-rich myocyte-speci¢c enhancer binding factor 2 (MEF2)
site, was identi¢ed [2]. Four proteins, termed MEF2A^D, that
bind the MEF2 DNA binding site were isolated in vertebrates.
MEF2 factors are thought to regulate myogenesis through the
ampli¢cation and maintenance of myogenic bHLH gene ex-
pression [3^10].
Several studies in tissue culture have shown di¡erences in
MRF function, including di¡erences in the ability to activate
both exogenous and endogenous promoters [11^18]. These
di¡erences may be due to their ability to remodel chromatin,
since MyoD, but not myogenin, has been shown to remodel
the chromatin of muscle-speci¢c genes in ¢broblasts [18].
Each MRF has a distinct pattern of expression in the de-
veloping mouse somite. The ¢rst MRF to be detected in the
myotome is myf5, followed by myogenin, MRF4, and MyoD
[19,20]. Of the MEF2 factors, MEF2C is expressed ¢rst at
about the same time as myogenin, followed by MEF2B, -A,
and -D [21,22]. Insight into the roles of the MRFs has been
gained from gene knockout studies in mice. The distinct phe-
notypes observed with the loss of individual MRFs, as well as
combinations of MRFs, have led to a model in which either
myf-5 or MyoD is required for the determination of skeletal
myoblasts and/or their propagation [23^25]. Furthermore,
myogenin plays an essential in vivo role in the terminal di¡er-
entiation of secondary ¢bers [26,27]. Using embryonic stem
(ES) cells lacking myogenin, it was shown that MyoD cannot
compensate for the absence of myogenin during ES cell di¡er-
entiation [28]. In summary, while each MRF binds to the
same core E box sequence, the mechanism by which the
MRFs activate di¡erent target genes is not clear.
P19 is a line of immortal mouse embryonal carcinoma cells
with a stable diploid karyotype. The di¡erentiation of these
pluripotent stem cells simulates the biochemical and morpho-
logical processes that occur during early embryonic develop-
ment [29]. In tissue culture, aggregation of P19 cells in the
absence of activating drug induces the expression of meso-
derm markers, but myogenesis does not occur. However, ag-
gregates treated with dimethylsulfoxide (DMSO) di¡erentiate
into cardiac and skeletal muscle along with other mesodermal
and endodermal cell types [30]. Skeletal muscle does not ap-
pear until day 9 following treatment and represents about 5%
of the population. Skeletal myogenesis in P19 cells requires
MRFs [31] and the overexpression of MRFs can initiate myo-
genesis following aggregation in the absence of DMSO
[32,33].
Using P19 cells expressing either MyoD or myogenin,
termed P19[MyoD] and P19[Mgn] cell lines, respectively, we
found that MEF2C expression paralleled the expression of
myogenin but not MyoD [33]. Since both MRFs induced sim-
ilar amounts of skeletal muscle, these results suggest that
myogenin selectively targets the upregulation of MEF2C ex-
pression, while MyoD does not.
The N- and C-terminal domains of the MyoD family mem-
bers have been shown to play discriminating roles in the trans-
activation of many muscle-speci¢c genes [11,14,15,34]. Using a
protein chimera strategy, these studies interchange the do-
mains surrounding the bHLH DNA binding/dimerization do-
main in order to transfer transiently expressed enhancer-spe-
ci¢c activation from one MRF to another. From these studies,
it was determined that both the myogenin N- and C-termini
cooperated in the targeted upregulation of a transiently ex-
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pressed reporter gene attached to a muscle-speci¢c enhancer
[11,14,15], while only the N-terminus of MyoD was found to
a¡ect a muscle-speci¢c response [11,14,34].
In order to determine which domain of myogenin targets
the upregulation of endogenous MEF2C in stably transfected
clones we generated a series of MyoD/myogenin chimeric pro-
teins. The results of these ¢ndings suggest that the myogenin
C-terminal region is responsible for targeting the upregulation
of MEF2C in P19 cells.
2. Materials and methods
2.1. Plasmid constructs
The three regions of MyoD and myogenin (N-terminus, bHLH, and
C-terminus) were generated by polymerase chain reaction (PCR) am-
pli¢cation with appropriate primers £anking the desired end points, as
shown in Fig. 1. Insertion of the HindIII and AccI sites into the PCR
fragments of MyoD and myogenin resulted in the mutation of single
amino acids at the junction (Fig. 1B). PCR reactions were carried out
with the primers shown in Fig. 1C, under standard conditions as
follows: 25 cycles of denaturation at 94‡C for 45 s, annealing for
1 min at 57‡C, and extension for 1 min at 72‡C. The ¢delity of
each PCR was con¢rmed by DNA sequencing.
All other expression plasmids were designed using the phosphogly-
cerate kinase (pgk-1) promoter to drive the expression of various
cDNAs and have been described previously [33].
2.2. Cell culture
P19 cells were obtained from the American Type Culture Collection
(No. CRL1825) and maintained, transfected, and di¡erentiated as
described previously [35^37]. For each calcium phosphate cotransfec-
tion a total of 12.5 Wg of plasmid was used: 1 Wg of PGK-lacZ, 1 Wg
of PGK-puro, 2.5 Wg of B17 [38], and 8 Wg of the desired expression
plasmid. Stable cell lines were isolated after selection in puromycin.
Di¡erentiation was performed by aggregating cells for 4 days in the
absence of DMSO, after which cells were plated into tissue culture
dishes. RNA was harvested or cells were ¢xed for immuno£uores-
cence on day 6 of di¡erentiation. Results were reproduced at least
twice with at least two cell lines.
2.3. Northern blot analysis
Total RNA was isolated on day 6 of di¡erentiation from P19 cell
lines and control cells by the lithium chloride/urea extraction method
and subsequent Northern blot analysis was performed as described
previously [39]. The probes used were a 600 bp PstI fragment of
human cardiac K-actin last exon [40], a 1.8 kb EcoRI fragment of
mouse MyoD cDNA [41], a 695 bp EcoRI/PstI fragment of rat my-
ogenin cDNA [42], and a 1.5 kb HindIII/XbaI fragment of MEF2C
cDNA [43]. All blots were standardized using a 750 bp EcoRI frag-
ment of rabbit 18S cDNA.
2.4. Immuno£uorescence
Cells were ¢xed in methanol at 320‡C for 5 min, rehydrated in
phosphate-bu¡ered saline for 15 min at room temperature, and sub-
sequently incubated with antibody. A mouse anti-myosin heavy chain
(anti-MyHC) monoclonal antibody (MF20) was used to stain for total
muscle myosin, as described previously [32]. Immuno£uorescence was
visualized with a Zeiss Axioscope microscope, images were captured
with a Sony 3CCD color video camera, and processed using Northern
Eclipse.
3. Results and discussion
Previous studies have shown that MyoD and myogenin ex-
hibited di¡erent target gene speci¢cities in aggregated P19
cells [33]. Myogenin upregulated the expression of MEF2C
while MyoD did not. To analyze the mechanism of this target
gene speci¢city, we created chimeric proteins containing do-
mains of both MyoD and myogenin. The chimeric proteins
were examined for their ability to activate MEF2C expression
and initiate myogenesis with a view to identifying the regions
of MyoD and myogenin responsible for their di¡erent bio-
chemical activities. These chimeras are described in Figs. 1
and 3.
To examine whether expression of each MyoD/myogenin
chimeric construct in P19 cells can induce di¡erentiation
into skeletal muscle, P19 and P19[Myo(XXX)] cells (where
XXX denotes either D for MyoD domain or G for Mgn
domain) were isolated and cell lines expressing high levels of
each construct were aggregated for 4 days and ¢xed on day 6.
Cells were examined by immuno£uorescence with antibody
directed against MyHC (Fig. 2). Bipolar skeletal myocytes
were visible in all cultures (Fig. 2B,D,F,H,J), but not in con-
trol cultures (data not shown). Therefore, the amino acid
changes shown in Fig. 1 did not a¡ect the ability of MyoD
or Mgn to induce myogenesis. Furthermore, these MyoD and
Mgn protein chimeras were all capable of inducing myogene-
sis in aggregated P19 cells.
In order to determine which protein chimeras could activate
MEF2C expression, total RNA was isolated from P19[Myo-
(DDD)], P19[Myo(GGG)], P19[Myo(DDG)], P19[Myo-
(GDG)], and P19[Myo(GDD)] cell lines on day 6 of di¡er-
entiation and subjected to Northern blot analysis. High levels
of MyoD or myogenin transcripts were present in all cultures
transfected with constructs encoding MyoD or myogenin do-
Fig. 1. A: Schematic diagram of the MyoD (white) and myogenin
(gray) proteins indicating the sites of mutation and the placement of
oligonucleotides for PCR ampli¢cation. The positions of oligonu-
cleotides used for ampli¢cation of each segment are labeled and the
amino acids are numbered. B: Amino acid substitutions required to
create restriction enzyme sites in MyoD and myogenin. The muta-
tions A100L and Q167V were made in the MyoD gene to create
HindIII and AccI sites, respectively. The mutation V72L was made
in the myogenin gene to create a HindIII site and the mutations
L139V and N140D were made to create an AccI site in myogenin.
C: Sequences of oligonucleotides (P1^12) used to amplify each seg-
ment of MyoD and myogenin.
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Fig. 2. MyoD/myogenin chimeric proteins induce skeletal muscle development in aggregated P19 cells. P19[Myo(DDD)] (A,B), P19[Myo(GGG)]
(C,D), P19[Myo(DDG)] (E,F), P19[Myo(GDG)] (G,H), and P19[Myo(GDD)] (I,J) were aggregated and examined on day 6 by immuno£uores-
cence after reaction with the anti-MyHC antibody, MF20 (observed magni¢cation 80U). Panels on the left show Hoechst staining of the nuclei.
Panels on the right show skeletal myocytes identi¢ed by MF20 reactivity.
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mains respectively (Fig. 3II, A,B). The formation of abundant
MRF-induced skeletal myocytes is indicated by the high levels
of cardiac K-actin expression present in all cultures (Fig. 3II,
C). Myogenin from Myo(GGG) and MyoD from Myo(DDD)
did not cross-activate each other’s expression to high levels
when compared to their exogenous expression levels in di¡er-
entiated cultures (Fig. 3II, A,B; lanes 1,2), suggesting that the
insertion of amino acid changes did not greatly modify the
function of MyoD and myogenin [33].
The ability of each clone to predominantly express one
MRF or the other allows these cell lines to be used as a
tool to study di¡erences in target gene speci¢city. In agree-
ment with previous results [33], we found that levels of
MEF2C expression were upregulated in cell lines expressing
myogenin [Myo(GGG)] but not MyoD [Myo(DDD)] (Fig. 3II,
D; lanes 1,2). Northern analysis also revealed that cell lines
expressing chimeras containing the myogenin C-terminus ex-
press comparatively high levels of MEF2C, (clones Myo-
(GGG), Myo(DDG), and Myo(GDG), Fig. 3II, D; lanes
2^4). Cell lines expressing chimeras lacking the myogenin
C-terminus did not express detectable levels of MEF2C
(clones Myo(DDD) and Myo(GDD) in Fig. 3II, D; lanes
1,5). This demonstrates a correlation between high levels of
expression of chimeric proteins containing the myogenin
C-terminus and MEF2C expression.
Attempts to further characterize the region responsible for
MEF2C upregulation to a speci¢c subdomain of the myoge-
nin C-terminus were made by swapping subdomains of the
myogenin C-terminus into the MyoD C-terminus. Unfortu-
nately, every C-terminal chimera examined upregulated en-
dogenous myogenin expression as well as MEF2C (data not
shown). Therefore, these experiments could not distinguish
between the ability of C-terminal chimeras to target the up-
regulation of MEF2C directly by targeting the MEF2C pro-
moter or indirectly by upregulating endogenous myogenin ex-
pression. Future studies will require the examination of
MyoD C-terminal chimeras in systems lacking endogenous
myogenin.
The C-terminal region of myogenin may act to target a
speci¢c gene by one or more mechanisms. This domain could
function by altering myogenin’s ability to bind DNA. Alter-
natively a change in protein^protein interaction could be used
to explain the di¡erences in function, as the myogenin C-ter-
minus contains a known transcriptional activation domain
[44]. Finally, it is possible that MEF2C upregulation may be
the consequence of a loss of wild-type MyoD structure. This
theory would assume that MyoD is normally in a ‘repressive’
conformation for MEF2C and myogenin expression.
The ¢nding that the C-terminus is responsible for di¡eren-
tial targeting of certain muscle-speci¢c promoters is in agree-
ment with previous studies [11,15,34]. In those studies, a do-
main swapping strategy was used to demonstrate that both
myogenin’s N- and C-termini cooperated to target the upreg-
ulation of a transiently expressed reporter gene attached to a
muscle-speci¢c enhancer, while only the N-terminus of MyoD
was found to a¡ect a muscle-speci¢c response. As shown pre-
viously [45], there are remarkable functional similarities be-
tween the N-termini of MyoD and myogenin, as they both
contain an acidic activation domain, and cysteine/histidine-
rich chromatin remodeling domains.
In summary, while it has been previously shown that MyoD
and myogenin exhibit di¡erent target gene speci¢cities in ag-
gregated P19 cells [33], the functional domain responsible for
this regulation had yet to be identi¢ed. The results of our
study con¢rm previous ¢ndings that myogenin preferentially
upregulates MEF2C [33] in P19 cells. Analysis of chimeric
proteins of myogenin and MyoD has revealed that myoge-
nin’s speci¢city for MEF2C upregulation can be localized to
its C-terminal domain.
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